2 results
Approved WMOWill not start
1. To compare the efficacy of tofacitinib, in doses of 2 mg, 5 mg, and 10 mg BID versus placebo on the ASAS20 response rate at Week 12 in subjects with active AS that have had an inadequate response to previous treatment.2. To estimate the placebo-…
Approved WMORecruiting
-To investigate whether a short-term treatment (3 months) with benfotiamine in diabetic nephropathy patients leads to a reduction in urinary excretion of β2-microglobulin and albumin.-To investigate whether short-term treatment (3 months) with…